FDA Approval Genetic Disease Life Science Marketing 
XTalks
DECEMBER 29, 2022
The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.
XTalks
DECEMBER 13, 2023
This approval also marks bluebird’s third ex vivo gene therapy approved by the FDA for a rare genetic disease and second FDA approval for an inherited hemoglobin disorder, cementing our position as a gene therapy leader.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
NOVEMBER 10, 2023
“As we strive to help patients with limited or no treatment options, developing innovative treatments in rare diseases is an inspiring challenge and one we have taken on for 70-plus years as a leader in hematology. The study evaluated both prophylactic and on-demand Adzynma ERT compared to plasma-based therapies in cTTP patients.
World of DTC Marketing
JANUARY 24, 2022
The amount of money required to gain approval of a new drug has been hotly debated, but it also costs a hell of a lot of money to launch a drug in today’s market. A study in 2020 estimated that the median cost of getting a new drug into the market was $985 million, and the average price was $1.3 Only about $2.2
XTalks
JANUARY 27, 2023
The website brings awareness for facial angiofibroma, an aspect of the rare genetic disease tuberous sclerosis complex (TSC). Hyftor became the first FDA-approved topical treatment for facial angiofibroma associated with tuberous sclerosis.
XTalks
MAY 17, 2023
In the past several years, gene therapies have finally been hitting the market after decades of setbacks and uncertainties. In the past several years, gene therapies have finally been hitting the market after decades of setbacks and uncertainties.
XTalks
NOVEMBER 27, 2023
Amicus Therapeutics has recently received approval from the US Food and Drug Administration (FDA) for its drugs Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) for adults living with late-onset Pompe disease (LOPD) who are not improving on their current enzyme replacement therapy (ERT).
Expert insights. Personalized for you.
52 
Let's personalize your content